The International journal on drug policy
February 1, 2017
Allison Matthews, Rachel Sutherland, Amy Peacock et al.
23 citations
Frequent psychostimulant consumers in Australia rated stimulant-type new psychoactive substances (NPS), such as mephedrone and methylone, less favorably than ecstasy and cocaine in terms of pleasurable effects and likelihood of future use. DMT, a hallucinogenic tryptamine, showed a similar profile to LSD for pleasurable effects and future use likelihood, but its negative acute and comedown effects were rated lower. Hallucinogenic phenethylamines like 2C-B had a negative profile similar to LSD but were rated as less pleasurable and less likely to be used again. The potential for expanded use of stimulant-type NPS may be lower than for common stimulants, while DMT's potential may be higher relative to LSD due to fewer negative effects.
Addiction
May 21, 2024
Shane Darke, Johan Duflou, Amy Peacock et al.
14 citations
From 2000 to 2023 in Australia, 43 deaths involving LSD (33 cases) or psilocybin (10 cases) were identified. Most deaths were from traumatic accidents (36.4% for LSD, 40.0% for psilocybin) or self-harm by physical means (12 cases, all involving LSD). Multiple drug toxicity accounted for about a fifth of deaths. Only one death was attributed solely to LSD toxicity, and two followed a cardiovascular event after LSD use. In four psilocybin cases the cause was undetermined. Severe agitation was the most common clinical presentation. Median blood concentrations were 0.8 μg/l for LSD and 20 μg/l for psilocin. Pre-existing organ pathology was uncommon.
The International journal on drug policy
November 1, 2021
Amy Peacock, Daisy Gibbs, Olivia Price et al.
12 citations
Over one-third of Australians who regularly use illegal stimulants reported testing their drugs' contents or purity, with 86% of those using a colorimetric reagent kit. Most testing occurred within 24 hours of planned use, and 24% tested for quantity. Among those testing a substance sold as MDMA, 87% detected MDMA. People who were younger, male, used new psychoactive substances, accessed community health services for drug reasons, sold drugs, or sought peer and online information were more likely to use drug checking. The findings suggest that in the absence of government-sanctioned services, people already engage in drug checking with suboptimal tools and without professional guidance.
Addiction (Abingdon, England)
January 1, 2025
Leigh Coney, Amy Peacock, Daan van der Gouwe et al.
8 citations
Drugs sold on cryptomarkets are not uniformly higher in quality than those bought offline. For MDMA tablets, MDMA powder, cocaine, and LSD, the advertised substance is more likely to be present when sourced from cryptomarkets. Strength is higher for cryptomarket MDMA powder, cocaine, and methamphetamine, but lower for MDMA tablets and amphetamine. Adulteration is less likely in cryptomarket MDMA powder and cocaine, but more likely in amphetamine and LSD. Cocaine from cryptomarkets also has fewer adulterants. The relationship between source and drug quality depends on the specific substance and market dynamics.
The International journal on drug policy
January 1, 2024
Leigh Coney, Amy Peacock, Aili Malm et al.
2 citations
People who buy MDMA, cocaine, or LSD from cryptomarkets are more likely to have no drug-using social network and to report adverse events requiring medical treatment. Among over 23,000 respondents from more than 70 countries in the 2018 Global Drug Survey, adverse events were low overall (5.2%). After controlling for age, gender, and frequency of use, recent cryptomarket use was associated with a higher likelihood of having no drug-using network for each drug. It was also linked to increased odds of adverse events for cocaine (adjusted odds ratio 1.70) and LSD (adjusted odds ratio 1.58). For those with a network larger than one person, cryptomarket use was still associated with more adverse LSD events. The findings suggest cryptomarket use may increase drug-related harm, but the complex mechanisms require further study.
Drug and alcohol review
May 1, 2025
Joel Keygan, Breanna Willoughby, Raimondo Bruno et al.
1 citation
Receiving a high-dose MDMA drug alert was associated with intentions to reduce or avoid the drug in a hypothetical scenario. In an online survey of Australians who had used MDMA pills or capsules in the past year, 45.4% of those shown an alert said they would not use the drug, compared to 20.7% of the control group. Among alert recipients, 46.7% said they would use and reduce their initial dose, versus 69.0% in the control group. Those who received an alert were about three times more likely to report intending not to use rather than taking a smaller dose, compared to the control group. Different phrasings of the alert did not significantly change intended behavior.
Drug and alcohol review
November 1, 2025
Jodie Grigg, Simon Lenton, Amy Peacock et al.
From 2021 to 2023, Australians who regularly used ecstasy or other stimulants and also used nitrous oxide showed a rise in use of large cylinders (from 6% to 26%) and a rise in reported neurological symptoms (from 5% to 14%). Most respondents knew about brain or nerve damage risks, but only one in five identified vitamin B12 depletion as a risk, and 17% were unaware of any risks. One-third took no precautions. Sourcing from convenience stores and 24/7 delivery services was common and linked to heavier use. Fewer than five people received treatment for symptoms. The authors call for balanced regulation and education of retailers, clinicians, and consumers.